UPCC 13423: A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR Cellular Therapies
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This study will evaluate the long-term (up to 15 years) safety and efficacy of CRISPR CAR cellular therapy for hematological and solid malignancies.
We would like to rely on WCG as the local IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 853908
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
